Johnson & Johnson (J&J) has chosen Pennsylvania as home to its new $1bn cell therapy manufacturing facility, as the Trump administration looks to onshore drug production to the US amid growing global competition. Once operational, the Montgomery County-based, next-generation production site will create more than 500 skilled biomanufacturing roles. The facility’s development will also open up 4,000 construction positions. The Pennsylvania facility will be J&J’s eleventh site within the state, which is alre ...

Core Insights - Johnson & Johnson (J&J) is optimistic about revenue growth, projecting 5-7% annual growth by 2026, with potential for double-digit growth in the 2030s, driven by oncology and other key sectors [1] Group 1: Revenue Growth Drivers - J&J identified six major growth drivers: three in pharmaceuticals (oncology, immunology, neuroscience) and three in medtech (surgery, cardiovascular, vision) [1] - Oncology is expected to generate $50 billion in revenue, with multiple myeloma (MM) sales projected to reach $25 billion by 2030 [2] Group 2: Oncology Portfolio - The largest franchise, Darzalex/Faspro (daratumumab), is anticipated to contribute over half of the MM sales, being central to many current and pipeline regimens [2] - J&J expects significant sales growth for Carvykti (ciltacabtagene autoleucel) despite market headwinds, with no supply restrictions and a focus on late-line patients [3] Group 3: Strategic Developments - J&J is developing a trispecific T-cell engager, ramantamig, currently in Phase I trials, and is working on leading in vivo CAR-T therapies through a partnership with Kelonia Therapeutics [4] - The company aims to maintain its dominance in MM by ensuring patients have access to J&J therapies across all treatment lines [3] Group 4: Underestimated Franchises - CEO Duato highlighted Rybrevant (amivantamab) and Lacluze (Lazertinib) as underestimated, with potential to outperform AstraZeneca's Tagrisso (Osimertinib) in NSCLC, projecting $6.3 billion in global sales by 2030 [5] - Inlexzo, an intravesical delivery system for gemcitabine, is expected to achieve $3.0 billion in global sales by 2030, with anticipated label expansions [5]